SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Vifor Pharma AG (GNHAY) trades at a trailing P/E of 46.8. Trailing earnings yield is 2.14%.
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 46.8).
- Trailing Earnings Yield 2.14% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
Overall SharesGrow Score: 67/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GNHAY
Valuation Multiples
P/E (TTM)46.8
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio6.84
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.82
Book Value / Share$0.00
Revenue / Share$5.61
FCF / Share$0.00
Yields & Fair Value
Earnings Yield2.14%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2012 |
$0.78 |
$3.29B |
$253.46M |
7.7% |
| 2013 |
$0.91 |
$3.36B |
$296.16M |
8.8% |
| 2014 |
$0.88 |
$3.42B |
$284.45M |
8.3% |
| 2015 |
$0.93 |
$3.79B |
$301.06M |
7.9% |
| 2016 |
$0.75 |
$4.12B |
$243.63M |
5.9% |
| 2017 |
$3.53 |
$1.34B |
$1.15B |
85.5% |
| 2018 |
$0.47 |
$1.58B |
$152.4M |
9.6% |
| 2019 |
$0.49 |
$1.88B |
$159.1M |
8.5% |
| 2020 |
$1.11 |
$1.71B |
$359.6M |
21.1% |
| 2021 |
$0.82 |
$1.82B |
$265.4M |
14.5% |
